Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib cream for moderate to severe atopic dermatitis
NCT03826901Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of delgocitinib in atopic dermatitis (AD) (2 arms), sponsored by LEO Pharma. Primary endpoint: Adverse events (AEs). Started Feb 2019; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03826901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826901.